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Background: The biomarkers soluble ST2 (sST2), galectin-3, and growth-differentiation factor-15 (GDF-15) pro-
vide prognostic information in patients with heart failure (HF). The aim of this study was to evaluate to which
extent plasma concentrations of these biomarkers are increased in HF compared with diverse non-cardiac con-
ditions such as infectious disease or chronic kidney disease.
Methods:Werecruited 15 patients in each of the following clinical categories:HFwithout co-morbidity, pneumo-
nia without co-morbidity, chronic obstructive pulmonary disease (COPD) without co-morbidity, HF and a co-
morbidity of pneumonia, renal disease without co-morbidity, and sepsis.We used 22 healthy individuals as con-
trol group. In each of the 112 study participants, we measured plasma concentrations of sST2 (Presage assay),
galectin-3 (Abbott assay) and GDF-15 (Roche assay).
Results: Compared to controls, the median sST2 concentration was ~2.5-fold increased in HF, ~3.5-fold in pneu-
monia, ~5.0-fold in COPD, ~5.8-fold in HF + pneumonia, and ~70-fold in sepsis (p b 0.001 for all). sST2 was not
signiﬁcantly increased in renal disease. Compared to controls, themedian galectin-3 concentrationwas ~1.5-fold
increased in HF, ~1.4-fold in pneumonia, ~2.4-fold in HF+ pneumonia, ~2.5-fold in renal disease, and ~2.7-fold
in sepsis (p b 0.001 for all). Galectin-3was not signiﬁcantly increased in COPD. Compared to controls, themedian
GDF-15 concentration was ~4.4-fold increased in HF, ~5.4-fold in pneumonia, ~2.1-fold in COPD, ~8.3-fold in
HF+pneumonia, ~5.1-fold in renal disease, and ~27-fold in sepsis (p b 0.001). In the 112 study participants, cor-
relation analyses revealed a relatively strong association between galectin-3 and GDF-15 (correlation coefﬁcient,
0.739; p b 0.001).
Conclusion: Because increased plasma concentrations of sST2, galectin-3, and GDF-15 are not speciﬁc for a distinct
disease group, the three biomarkers are not useful for diagnostic purposes. The results of our study are novel with
respect to sST2, galectin-3 and GDF-15 as markers of inﬂammatory diseases and should encourage further studies.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The three proteins soluble ST2 (sST2), galectin-3, and growth-
differentiation factor-15 (GDF-15) are currently gaining mounting in-
terest as candidate biomarkers in heart failure (HF) [1–3]. There is in-
creasing evidence that plasma concentrations of these three analytes
provide prognostic information in HF patients independently of and ad-
ditive to other established markers such as cardiac troponins or natri-
uretic peptides [1–4]. Among them, the biomarkers sST2 and galectin-
3 have been included in the 2013 ACCF/AHA guideline for additive risk
stratiﬁcation of patients with acute and chronic HF [4].
To date, no comparative data has beenpublished towhich extent plas-
ma concentrations of sST2, galectin-3, andGDF-15 are increased in clinicalry Medicine, Konventhospital
ria. Fax: +43 732 7677 3799.
).
. This is an open access article underconditions often being associated with HF (e.g., pneumonia, chronic ob-
structive pulmonary disease [COPD], or renal failure). This is of interest
because increased concentrations of the three biomarkers in various
other diseases besides HF could modify the diagnostic and prognostic
value of sST2, galectin-3, and GDF-15 for HF. The aim of this study was,
therefore, to evaluate to which extent plasma concentrations of sST2,
galectin-3, and GDF-15 are increased in HF compared with diverse non-
cardiac conditions such as infectious disease, or chronic kidney disease.2. Materials and methods
2.1. Study protocol
This is a single center study performed at the St. John of GodHospital
in Linz, Austria. As part of an evaluation study of a novel high-sensitivity
assay for measurement of sST2 [5], we recruited a cohort of patientsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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verse clinical conditions or not. In brief, we enrolled 15 inpatients
each with ‘heart failure (HF) without co-morbidity’, ‘pneumonia with-
out co-morbidity’, ‘COPD without co-morbidity’, ‘HF with co-morbidity
of pneumonia’, ‘renal disease without co-morbidity’, and ‘sepsis’. Using
this approach, we aimed at disentangling various clinical conditions
suspected to increase the concentrations of sST2 as accurately as possi-
ble. In addition, we used 22 healthy members of our laboratory staff as
the control group. From each of the 112 study participants, several plas-
ma aliquots were stored at−80 °C. This was done to give us the oppor-
tunity to determine other novel biomarkers of potential interest from
this cohort in the future. The local ethics committee approved this
study protocol in accordance with the Declaration of Helsinki [5]. All
study participants gave informed consent [5].
The present work is a retrospective explorative analysis because it
was a post-hoc decision to measure galectin-3 and GDF-15 from the
plasma aliquots stored at−80 °C. As detailed previously, the data on
sST2 in this cohort have been already published [5]. We now intended
to compare these results on sST2 with the results of galectin-3 and
GDF-15measurements in those same patients of our well characterized
cohort.
2.2. Deﬁnitions
Arterial hypertension was deﬁned as resting systolic blood pressure
≥140mmHg, or resting diastolic blood pressure≥90mmHgor the use
of any antihypertensive medication. Diabetes mellitus was deﬁned as
fasting blood glucose levels ≥126 mg/dL or the use of any glucose-
lowering medication. Current smoking was deﬁned as any amount of
tobacco use. Left ventricular ejection fraction (LVEF) was determined
by echocardiography andwas quantiﬁed as≥50% or b50%. Coronary ar-
tery disease (CAD)was deﬁned as previousmyocardial infarction or un-
stable angina by history, or as previous percutaneous transluminal
coronary angioplasty or coronary bypass surgery. The diagnosis of atrial
ﬁbrillation was deﬁned as ﬁrst episode, paroxysmal, persistent, or
permanent.
‘HF without co-morbidity’was deﬁned as clinical condition with typ-
ical symptoms and signs of acute destabilized HF (e.g., dyspnea, jugular
venous distension, pulmonary rales, edema of the legs or feet) according
to the Framingham criteria for the clinical diagnosis of HF [5,6], evidence
of heart enlargement by chest radiograph and/or evidence of systolic dys-
function by echocardiography, response to adequate HF therapy, and B-
type natriuretic peptide (BNP) plasma concentrations N500 pg/mL, but
without a clinical diagnosis of pneumonia, COPD or renal disease and
without any laboratory evidence of inﬂammation or renal disease
(i.e., C-reactive plasma protein [CRP] ≤1.0 mg/dL, procalcitonin [PCT]
≤0.5 ng/mL, interleukin-6 [IL-6]≤15.0 pg/mL, and estimated glomerular
ﬁltration rate [eGFR] N90 mL/min/1.73 m2) [5].
‘Pneumonia without co-morbidity’ was deﬁned as community-
acquired pneumonia with symptoms and signs consistent with a lower
respiratory tract infection (e.g., cough, sputum production, dyspnea,
fever, auscultatory ﬁndings of abnormal breath sounds and crackles) as-
sociated with a new pulmonary opacity on chest radiograph compatible
with pneumonia and response to antimicrobial therapy [5,7] but without
a clinical diagnosis of HF, COPD or renal disease and without any labora-
tory evidence of renal disease or HF (i.e., eGFR N90 mL/min/1.73 m2,
and BNP ≤100 pg/mL) [5].
‘COPD without co-morbidity’ was deﬁned as exacerbated disease
with acuteworsening of respiratory symptoms (e.g., increased dyspnea,
productive cough with altered sputum, wheezing, fever, fatigue) [5,8],
andwasbased on clinical history, physical examination, and spirometric
criteria (FEV1 b 50% predicted and FEV1/VC ratio b70%) and response
treatment with oral corticosteroids or antibiotics, or both but without
a clinical diagnosis of HF, pneumonia or renal disease and without any
laboratory evidence of renal disease or HF (i.e., eGFR N90 mL/min/
1.73 m2, and BNP ≤100 pg/mL) [5].‘HF with co-morbidity of pneumonia’ was deﬁned as HF with addi-
tional pneumonia according to the deﬁnitions as described previously
in this chapter [5].
‘Renal disease without co-morbidity’ was deﬁned as non-dialysis
chronic kidney disease [5,9] associated with an eGFR b60 mL/min/
1.73 m2 but without a clinical diagnosis of HF, pneumonia, or COPD and
without any laboratory evidence of HF or inﬂammation (i.e., BNP
≤100 pg/mL, CRP ≤1.0 mg/dL, PCT ≤0.5 ng/mL, and IL-6 ≤ 15.0 pg/mL)
[5].
‘Sepsis’was deﬁned as severe sepsis or septic shock according to the
criteria of the American College of Chest Physicians/Society of Critical
Care Medicine consensus conference [5,10].
2.3. Blood collection, routine analyte determination, and aliquot storage
We obtained blood by venipuncture avoiding venous stasis. Using
VACUETTE® polyethylene terephthalate glycol blood collection tubes
(Greiner Bio-One, Kremsmuenster, Austria), we collected one EDTA
anticoagulated blood sample and one serum sample. We quantiﬁed
serum concentrations of CRP, PCT, IL-6, and creatinine, plasma concen-
trations of BNP, and eGFR within 4 h of blood collection in clinical rou-
tine, as described previously [5]. Several plasma aliquots from each
study participant were frozen at−80 °C and stored until analysis. Plas-
ma concentrations of sST2 were measured from a thawed aliquot in
2009 [5]. Plasma concentrations of galectin-3 and GDF-15 were mea-
sured in one batch from another thawed aliquot in 2014. Plasma con-
centrations of high sensitive cardiac troponin I (hs-cTnI) were
measured in one batch from another thawed aliquot on an Architect
system (Abbott Diagnostics, Vienna, Austria) in 2015. Based to the ana-
lytical sensitivity of this assay reported in the package insert, hs-cTnI
concentrations ≤1.5 ng/L were reported as 1.5 ng/L.
2.4. Measurement of sST2, galectin-3 and GFD-15 plasma concentrations
Wemeasured sST2plasma concentrations on a BEP 2000 instrument
(Siemens Medical Solutions Diagnostics, Vienna, Austria) with the Pre-
sage ST2 assay (Critical Diagnostics, San Diego, CA, USA) as previously
described [5]; this enzyme-linked immunosorbent assay has ameasure-
ment range of 2.8–180 ng/mL (based on a 45-fold dilution of patient
samples). We measured galectin-3 plasma concentrations with a
chemiluminescent microparticle immunoassay on an ARCHITECT
I2000SR analyzer (Abbott Laboratories, Abbott Park, IL, USA) [11]; ac-
cording to the package insert this assay has a measurement range of
4–114 ng/mL. We measured GDF-15 plasma concentrations with a
pre-commercial chemiluminescent microparticle immunoassay on
a Hitachi cobas e411 analyzer (Roche Diagnostics, Mannheim,
Germany); according to the manufacturer, this assay has a measure-
ment range of 400–20,000 pg/mL.
If the analyte concentration of a patient sample exceeded the analyt-
ical range of one of the three assays, the respective sample was assayed
in various dilutions if necessary to obtain the actual value. Based to the
analytical sensitivity of the assays, sST2 concentrations ≤2.8 ng/mL
were reported as 2.8 ng/mL, galectin-3 concentrations ≤4 ng/mL were
reported as 4 ng/mL, and GDF-15 concentrations≤400 pg/mL were re-
ported as 400 pg/mL in the present work.
We evaluated the precision of the sST2 assay in 2009, and the preci-
sion of the GDF-15 and galectin-3 assays in 2014, applying the same
protocol according to the Clinical and Laboratory Standards Institute
(CLSI; formerly NCCLS) guideline EP5-A [12]. For each of the three as-
says, we used the same three pooled patient plasma samples (pools
1–3)whichwe had aliquoted into twenty plastic tubes for each concen-
tration level and frozen at−80 °C.We analyzed these samples in dupli-
cate in one run per day for 20 days with the three assays. Within-run
and total analytical imprecision (CV) was calculated with the CLSI
single-run precision evaluation test [12] for each assay.
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CV of 2.4% and a total CV of 4.0% at a mean concentration of 11 ng/mL
(pool 1), a within-run CV of 2.0% and a total CV of 3.9% at a mean con-
centration of 87 ng/mL (pool 2), and a within-run CV of 2.2% and a
total CV of 3.9% at a mean concentration of 140 ng/mL (pool 3).
The Abbott galectin-3 assay had a within-run CV of 3.6% and a total
CV of 4.9% at a mean concentration of 16 ng/mL (pool 1), a within-run
CV of 1.8% and a total CV of 2.6% at a mean concentration of 22 ng/mL
(pool 2), and a within-run CV of 2.8% and a total CV of 4.5% at a mean
concentration of 32 ng/mL (pool 3).
The Roche GDF-15 assay had a within-run CV of 2.1% and a total CV
of 5.4% at a mean concentration of 483 pg/mL (pool 1), a within-run CV
of 1.4% and a total CV of 6.5% at a mean concentration of 5659 pg/mL
(pool 2), and a within-run CV of 0.8% and a total CV of 6.1% at a mean
concentration of 7719 pg/mL (pool 3).2.5. Statistical analyses
We analyzed our data with the SPSS 13.0 software (SPSS Inc., Chica-
go, IL, USA) and the MedCalc 13.0.0.0 package (MedCalc Software,
Mariakerke, Belgium). Dichotomous variables are given as absolute
numbers and continuous variables as median (range). Comparisons of
continuous variables between patient groups were performed with
the non-parametric Mann–Whitney U test. Relationships between con-
tinuous variables are described bymeans of the Spearman coefﬁcient of
rank correlation with 95% conﬁdence intervals (95% CI). Obtained pTable 1
Characteristics of the study participants according to the different disease groups.
Controls
(n = 22)
HF
(n = 15)
Pneumonia
(n = 15)
COPD
(n =
Male gender 12 11 13 14
Age (years) 38 (22–59) 72 (57–85) 57 (25–84) 63 (5
BMI (kg/m2) 23 (19–34) 24 (17–35) 25 (19–35) 24 (1
Hypertension 0 11 5 6
Diabetes mellitus 0 3 4 3
Current smoking 7 4 4 5
LVEF b50% 0 15 0 0
CAD 0 8 1 2
Atrial ﬁbrillation 0 7 3 1
CRP (mg/dL) 0.1 (0.1–1.0) 0.6 (0.1–1.0) 14 (2.8–29) 0.3 (
PCT (ng/mL) 0.1 (0.1–0.2) 0.1 (0.1–0.4) 0.2 (0.1–2.8) 0.1 (
IL-6 (pg/mL) 2.0 (2.0–14) 4.6 (2.0–15) 48 (7–245) 2.0 (
eGFR (mL/min/
1.73 m2)
N90
(N90–N90)
N90 (N90–N90) N90 (N90–N90) N90
BNP (pg/mL) 17 (10–95) 880 (519–3109) 66 (17–96) 48 (1
hs-cTnI (ng/L) 1.8 (1.5–15.7) 34.8 (2.6–116.0) 5.0 (1.5–33.0) 2.5 (
sST2 (ng/mL) 11 (6–33) 27 (11–132)*** 39 (19–765)*** 56 (8
sST2 values N URLa 0 3 5 9
Galectin-3 (ng/mL) 13 (7–21) 20 (10–42)*** 18 (9–49)** 14 (1
Galectin-3 values N
URLb
0 3 5 0
GDF-15 (pg/mL) 602
(400–1144)
2636
(843–6889)***
3212
(400–17,986)***
1269
(596
GDF-15 values N URLc 1 7 10 1
Abbreviations: BMI, bodymass index; BNP, B-type natriuretic polypeptide; CAD, coronary arter
timated glomerular ﬁltration rate; GDF-15, growth-differentiation factor-15; HF, heart failure; h
fraction; PCT, procalcitonin; sST2, soluble ST2; URL, upper reference limit.
Data are presented as number or median (range). Difference of sST2, galectin-3 and GDF-15 co
Mann–Whitney-U test (p-values were not corrected for multiple comparisons): ***p b 0.001, *
a The number of patients with sST2 plasma concentrations greater than the upper reference
Diego, CA, USA). Based on the 95th percentiles of a healthy reference population, the age-indep
for female individuals.
b The number of patients with galectin-3 plasma concentrations greater than the upper refer
Abbott Park, IL, USA). Based on the 97.5th percentiles of a healthy reference population, the age
28.7 ng/mL for female individuals.
c The number of patients with GDF-15 plasma concentrations greater than the upper refere
luminescentmicroparticle immunoassay (Roche Diagnostics, Mannheim, Germany) [31]. Based
theupper reference limits for galectin-3were ranging from1498 ng/L formale individuals in the
4th decade to 2562 ng/L in the 8th decade.values were not adjusted for multiple comparisons and are therefore
descriptive only.3. Results
The results of our clinical evaluation study are detailed in Table 1.
The distribution of sST2, galectin-3 and GDF-15 plasma concentrations
in the control group and in the disease groups are displayed in Fig. 1.
The results indicate that there is no relevant difference of sST2 plas-
ma concentrations between the control group and the patients with
renal disease (p = 0.065). In contrast, increased sST2 concentrations
were obtained in the patients with HF (p b 0.001), pneumonia
(p b 0.001), COPD (p b 0.001), and sepsis (p b 0.001). Compared to
healthy controls, the median plasma concentrations of sST2 are ~2.5-
fold increased in HF, ~3.5-fold increased in pneumonia, ~5.0-fold in-
creased in COPD, ~5.8-fold increased in HF with co-morbidity of pneu-
monia, and ~70-fold increased in sepsis.
For galectin-3, increased analyte concentrations are evident in the
patients with HF (p b 0.001), pneumonia (p = 0.001), renal disease
(p b 0.001), and sepsis (p b 0.001). In contrast, galectin-3 plasma con-
centrations are not signiﬁcantly different in healthy controls and pa-
tients with COPD (p = 0.070). Compared to healthy controls, the
median plasma concentrations of galectin-3 are ~1.5-fold increased in
HF, ~1.4-fold increased in pneumonia, ~2.4-fold increased in HF with
co-morbidity of pneumonia, ~2.5-fold increased in renal disease, and
~2.7-fold increased in sepsis.15)
HF + pneumonia
(n = 15)
Renal disease
(n = 15)
Sepsis
(n = 15)
12 12 9
1–82) 80 (55–96) 74 (55–83) 70 (35–83)
9–33) 24 (20–36) 22 (19–30) 25 (18–40)
10 13 7
7 7 1
0 0 3
15 0 7
9 4 7
4 1 5
0.1–18) 8.4 (5.8–30) 0.1 (0.1–1.0) 25 (7.6–35)
0.1–0.4) 0.1 (0.1–2.2) 0.1 (0.1–0.4) 32 (7.0–280)
2.0–16) 43 (10–1088) 2.1 (2.0–10) 1132 (112–65,500)
(N90–N90) N90 (N90–N90) 29 (10–56) 43 (12–N90)
0–91) 864 (539–4793) 51 (30–96) 697 (37–2575)
1.5–24.9) 40.8 (8.9–106.1) 7.8 (2.3–35.6) 71.1 (12.7–180.9)
–341)*** 64 (21–158)*** 13 (8–34)‡ 745 (111–4056)***
10 0 15
0–24)‡ 31 (12–85)*** 33 (17–68)*** 35 (11–107)***
8 10 11
–2158)***
4974
(2218–15,054)***
3090
(2167–9174)***
16,127
(4775–33,454)***
10 9 15
y disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; eGFR, es-
s-cTnI, high-sensitivity cardiac troponin I; IL-6, interleukin-6; LVEF, left ventricular ejection
ncentrations of the control group vs. each of the disease groups were calculated with the
*p b 0.01, and ‡p N 0.05.
limits as derived from the package insert of the Presage ST2 assay (Critical Diagnostics, San
endent upper reference limits for sST2 are 49.3 ng/mL for male individuals and 33.5 ng/mL
ence limits as derived from the package insert of the galectin-3 assay (Abbott Laboratories,
-independent upper reference limits for galectin-3 are 26.1 ng/mL formale individuals and
nce limits as derived from a study by Ho and co-workers using a pre-commercial chemi-
on 97.5th percentiles by 10-year age and sex categories of a healthy reference population,
4th decade to 5006ng/L in the 8th decade and from1085ng/L for female individuals in the
Fig. 1. Distribution of (A) sST2, (B) galectin-3, (C) and GDF-15 plasma concentrations in
healthy individuals vs. diseased patients. Themultiple comparison graphs show the distri-
bution of the three biomarkers in healthy individuals (Healthy, n = 22) compared to pa-
tients with heart failure (HF, n = 15), to patients with pneumonia (Pneum, n = 15), to
patients with chronic obstructive pulmonary disease (COPD, n = 15), to patients with
HF and co-morbidity of pneumonia (HF + Pneum, n= 15), to patients with renal disease
(Renal, n= 15), and to patients with sepsis (Sepsis, n = 15), respectively. In each disease
category all data were plotted as open circles, and the horizontal lines represent the me-
dian analyte concentration of each disease category.
Fig. 2. Scatterplots of (A) sST2 plasma concentrations vs. galectin-3 plasma concentra-
tions; (B) sST2 plasma concentrations vs. GDF-15 plasma concentrations; and
(C) galectin-3 plasma concentrations vs. GDF-15 plasma concentrations in the 112 study
participants. In each graph, the plasma concentrations of each of the 112 study participant
were plotted as open circles. The method comparison graphs display the results of
Spearman rank correlation.
158 T. Mueller et al. / Clinica Chimica Acta 445 (2015) 155–160GDF-15 plasma concentrations are increased in all disease groups
evaluated in this study (p b 0.001 for each). Compared to healthy con-
trols, the median plasma concentrations of GDF-15 are ~4.4-foldincreased in HF, ~5.4-fold increased in pneumonia, ~2.1-fold increased
in COPD, ~8.3-fold increased in HF with co-morbidity of pneumonia,
~5.1-fold increased in renal disease, and ~27-fold increased in sepsis.
As a secondary ﬁnding, hs-cTnI plasma concentrations are markedly
increased in HF (with or without co-morbidity of pneumonia) and in
sepsis as shown in Table 1.
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tween sST2 and GDF-15, and between galectin-3 and GDF-15, respec-
tively, in the entire cohort of the 112 study participants. Non-
parametric correlation analyses revealed Spearman's coefﬁcient of
rank correlations of 0.355 (95% CI, 0.182–0.507; p = 0.355) for sST2
vs. galectin-3, of 0.612 (95% CI, 0.482–0.717; p b 0.001) for sST2 vs.
GDF-15, and of 0.739 (95% CI, 0.641–0.813; p b 0.001) for galectin-3
vs. GDF-15.
4. Discussion
The main ﬁnding of the present study was that the plasma concen-
trations of the three biomarkers sST2, galectin-3, and GDF-15 were in-
creased not only in HF but also in several other non-cardiac diseases.
In HF and other diverse non-cardiac conditions such as infectious dis-
ease, or chronic kidney disease, however, the magnitude of the incre-
ment for sST2, galectin-3, and GDF-15 differs considerably. Compared
to healthy controls, sST2 was increased ~2.5-fold in HF, galectin-3
~1.5-fold, and GDF-15 ~4.4-fold. In pneumonia for example, sST2 was
increased ~3.5-fold, galectin-3 ~1.4-fold, and GDF-15 ~5.4-fold; and in
sepsis, sST2 was increased ~70-fold, galectin-3 ~2.7-fold, and GDF-15
~27-fold. In general, across most of the disease groups of this study,
sST2 andGDF-15 plasma concentrations seem to have a greater amount
of increase compared with plasma concentrations of galectin-3. Thus,
there is a different behavior of the three analytes in variousmedical con-
ditions which can be explained by different pathophysiological func-
tions of these biomarkers. Nevertheless, we saw associations between
the three markers as demonstrated by correlation analyses; especially
the relationship between galectin-3 and GDF-15 was relatively strong
in our study.
It is well known from the literature that cardiac troponins are often
increased in HF [1,3] and in sepsis [13], and that cardiac troponins are
considered prognostic markers in both conditions [1,3,13]. Similarly,
hs-cTnI plasma concentrations were markedly increased in HF and in
sepsis in our study as well.
ST2 is an interleukin-1 receptor family member with transmem-
brane (ST2L) and soluble isoforms (sST2) [14–17]. ST2L is a membrane
bound receptor, and interleukin-33 (IL-33) is the functional ligand for
ST2L [14–17]. In principle, IL-33 functions as a danger signal or an
alarmin by signaling the presence of tissue damage to local immune
cells after exposure to pathogens, injury-induced stress, or death by ne-
crosis [15–17]. IL-33/ST2L signaling leads to inﬂammatory gene tran-
scription and ultimately to the production of inﬂammatory cytokines/
chemokines and induction of immune response [16,17]. sST2, a soluble
truncated form of ST2L, is secreted into the circulation and is believed to
function as a “decoy” receptor for IL-33, inhibiting the effects of IL-33/
ST2L signaling [14–17]. Thus, increased concentrations of sST2 in the
circulation attenuate the systemic biologic effects of IL-33. Blood con-
centrations of sST2 are signiﬁcantly increased, e.g., in inﬂammatory/in-
fectious diseases, in cancer and in cardiac disease but not in chronic
kidney disease [1–3,5,16,17]. The major source of circulating sST2 in
healthy individuals and in patients with distinct diseases (especially in
human cardiac disease) is, however, currently not established [16,17].
Galectin-3 is a unique member of chimera type galectins and is in-
volved in a large number of disease processes [18,19]. Galectin-3 con-
tains a carbohydrate-recognition-binding domain that enables the
speciﬁc binding ofβ-galactosides [18,19]. Galectin-3 exhibits both intra-
cellular and intracellular functions and it has a concentration dependent
ability to be monomeric or form oligomers [18,19]. Galectin-3 is in-
volved in cell adhesion, activation, proliferation, apoptosis as well as
cell migration [18–20]. It plays an important role not only in cancer
[21] but also in inﬂammation [18,19,21]. In this context, galectin-3 can
be viewed as regulatory protein acting at several stages along the con-
tinuum from acute inﬂammation to chronic inﬂammation and tissue
ﬁbrinogenesis [18]. Indeed, the involvement of galectin-3 in various “in-
ﬂammatory/ﬁbrotic” conditions such as arthritis, asthma, pneumonia,atherosclerosis, and kidney disease has been described [18,19,21].
Even in the pathophysiology of HF, galectin-3 plays a biological role
through inﬂammation and ﬁbrosis [1–3,21].
GDF-15 is a protein belonging to the transforming growth factor
beta superfamily that has a role in regulating inﬂammatory and apo-
ptotic pathways in acute and chronic tissue injury [22–25]. The ex-
pression of GDF-15 in virtually all tissues suggests its importance in
general and basic cellular functions [22,23]. The expression of GDF-
15 is upregulated in many different pathological conditions, includ-
ing inﬂammation, cancer, cardiovascular disease, pulmonary dis-
ease, diabetes, and renal disease [22–27]. On a molecular level,
GDF-15 expression seems to be controlled by, e.g., the ubiquitous
transcription factor p53, which responds to various cellular stress
signals, such as hypoxia, ischemia, oxidative stress, inﬂammation,
or acute tissue injuries [24,25]. Plasma concentrations of GDF-15
are believed to reﬂect these stressors and their role on disease pro-
gression and prognosis [25]. Notably, the receptor of GDF-15 and
the downstream signaling pathways that drive its action are current-
ly not established [22,24]. In addition, it is still unclear whether in-
creased plasma concentrations of GDF-15 can cause direct damage
or may represent a protective response to biologic stress [23].
Taken together, the three biomarkers sST2, galectin-3, and GDF-15
are not speciﬁc for a distinct medical condition but rather represent
general markers of disease and mortality [16–27]. Because increased
plasma concentrations of sST2, galectin-3, and GDF-15 are not speciﬁc
for a distinct disease group as demonstrated in this study, we conclude
that the three biomarkers are of limited value for diagnostic purposes.
For example, in emergency patients with acute shortness of breath, nei-
ther of three biomarkers can be considered useful for differentiating be-
tween dyspnea attributable to acute HF and dyspnea attributable to
other causes, e.g., pneumonia or COPD.
On the other hand, there is a large body of evidence indicating that
these three markers are valuable prognosticators for mortality end-
points in a broad spectrumof diseases aswell as in population-based co-
horts [16,17,21–27]. In addition to this, we would like to draw the
attention to another issue of the potential of the three markers for
prognostic purposes. In an emergency setting of acute dyspnea, it
is well known that coincidence of HF and pulmonary disease
(e.g., pneumonia or COPD) is common and also related to worse out-
come [28–30]. Because plasma concentrations of sST2, galectin-3 and
GDF-15 were increased in our patients with HF and co-morbidity of
pneumonia compared to the patients suffering from HF without any
co-morbidity or from pneumonia without any co-morbidity, the in-
creased plasma concentrations of the three analytes in HF and concom-
itant pneumonia might reﬂect the increased mortality rates in this
group. However, these considerations deserve further study.
A limitation of our study is certainly the small number of study par-
ticipants in each disease group. However, after screening a huge num-
ber of patients in our hospital, we were able to completely disentangle
various clinical conditions suspected to increase the concentrations of
the analytes with our study design. We further acknowledge that that
proportion of male was greater in every group compared to the control
group, and that the individuals of the control group were younger than
those of the other groups. In addition, this study was designed to evalu-
ate plasma concentrations of sST2 in various diseases, and it was a post-
hoc decision to measure galectin-3 and GDF-15 plasma concentrations
in our cohort. Thiswas the reasonwhywe decided to rely on descriptive
statistics only in our evaluation study and not to adjust for multiple
comparisons. However, our study should be considered explorative
and hypothesis generating for future work. In addition, we would like
to further acknowledge that we havemeasured the biomarkers of inter-
est at one time point only. It would be intriguing to have multiple serial
measurements in time course to see how the biomarkers behave as a
consequence of treatment initiation. This knowledge could reﬁne the
prognostic value of the novel biomarkers sST2, galectin-3 and GDF-15
in the different disease groups evaluated in this study.
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BMI body mass index
BNP B-type natriuretic peptide
CAD coronary artery disease
COPD chronic obstructive pulmonary disease
CRP C-reactive protein
eGFR estimated glomerular ﬁltration rate
GDF-15 growth-differentiation factor-15
HF heart failure
hs-cTnI high-sensitivity cardiac troponin I
IL-6 interleukin-6
LVEF left ventricular ejection fraction
PCT procalcitonin
sST2 soluble ST2
URL upper reference limit
References
[1] Gaggin HK, Januzzi Jr JL. Biomarkers and diagnostics in HF. Biochim Biophys Acta
1832;2013:2442–50.
[2] Schmitter D, Cotter G, Voors AA. Clinical use of novel biomarkers in heart failure: to-
wards personalized medicine. Heart Fail Rev 2014;19:369–81.
[3] Pouleur AC. Which biomarkers do clinicians need for diagnosis and management of
heart failure with reduced ejection fraction? Clin Chim Acta 2015;443:9–16.
[4] Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation;
American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA
guideline for the management of heart failure: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on Practice Guide-
lines. J Am Coll Cardiol 2013;62:e147–239.
[5] Dieplinger B, Januzzi Jr JL, Steinmair M, et al. Analytical and clinical evaluation of a
novel high-sensitivity assay for measurement of soluble ST2 in human plasma—the
Presage ST2 assay. Clin Chim Acta 2009;409:33–40.[6] Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the commu-
nity: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation
1998;98:2282–9.
[7] Niederman MS, Mandell LA, Anzueto A, et al. American Thoracic Society. Guidelines
for the management of adults with community-acquired pneumonia. Diagnosis, as-
sessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care
Med 2001;163:1730–54.
[8] Burge S,Wedzicha JA. COPD exacerbations: deﬁnitions and classiﬁcations. Eur Respir
J 2003;21:46S–53S.
[9] Levey AS, Eckardt KU, Tsukamoto Y, et al. Deﬁnition and classiﬁcation of chronic kid-
ney disease: a position statement from Kidney Disease: Improving Global Outcomes
(KDIGO). Kidney Int 2005;67:2089–100.
[10] American College of Chest Physicians/Society of Critical Care Medicine Consensus
Conference: deﬁnitions for sepsis and organ failure and guidelines for the use of in-
novative therapies in sepsis. Crit Care Med 1992;20:864–74.
[11] La'ulu SL, Apple FS, Murakami MM, Ler R, Roberts WL, Straseski JA. Performance
characteristics of the ARCHITECT galectin-3 assay. Clin Biochem 2013;46:119–22.
[12] Standards Institute Laborator Clinical. Evaluation of precision performance of clinical
chemistry devices; approved guideline. CLSI Document EP5-A. Wayne, PA: CLSI;
1999.
[13] Bessière F, Khenifer S, Dubourg J, Durieu I, Lega JC. Prognostic value of troponins in
sepsis: a meta-analysis. Intensive Care Med 2013;39:1181–9.
[14] Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in
the IL-1 family. Nat Rev Immunol 2010;10:103–10.
[15] Villarreal DO, Weiner DB. Interleukin 33: a switch-hitting cytokine. Curr Opin
Immunol 2014;28C:102–6.
[16] Mueller T, Jaffe AS. Soluble ST2 — analytical considerations. Am J Cardiol 2015;
115(7S):8B–21B.
[17] Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta 2015;443C:
57–70.
[18] Henderson NC, Sethi T. The regulation of inﬂammation by galectin-3. Immunol Rev
2009;230:160–71.
[19] Gao P, Simpson JL, Zhang J, Gibson PG. Galectin-3: its role in asthma and potential as
an anti-inﬂammatory target. Respir Res 2013;14:136.
[20] Song L, Tang JW, Owusu L, Sun MZ, Wu J, Zhang J. Galectin-3 in cancer. Clin Chim
Acta 2014;431:185–91.
[21] Ravani P, Barrett BJ. Galectin-3 and new-onset CKD: marker or mediator? J Am Soc
Nephrol 2013;24:1342–4.
[22] Corre J, Hébraud B, Bourin P. Concise review: growth differentiation factor 15 in pa-
thology: a clinical role? Stem Cells Transl Med 2013;2:946–52.
[23] Lindahl B. The story of growth differentiation factor 15: another piece of the puzzle.
Clin Chem 2013;59:1550–2.
[24] Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic
functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 2010;224:
626–35.
[25] Kempf T, Wollert KC. Risk stratiﬁcation in critically ill patients: GDF-15 scores in
adult respiratory distress syndrome. Crit Care 2013;17:173.
[26] Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update.
Curr Heart Fail Rep 2012;9:337–45.
[27] Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-β family cytokine
growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine
Growth Factor Rev 2013;24:373–84.
[28] Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic
value of established and novel biomarkers in patients with shortness of breath at-
tending an emergency department. Clin Biochem 2010;43:714–9.
[29] Thomsen RW, Kasatpibal N, Riis A, Nørgaard M, Sørensen HT. The impact of pre-
existing heart failure on pneumonia prognosis: population-based cohort study. J
Gen Intern Med 2008;23:1407–13.
[30] Macchia A, Monte S, Romero M, D'Ettorre A, Tognoni G. The prognostic inﬂuence of
chronic obstructive pulmonary disease in patients hospitalised for chronic heart fail-
ure. Eur J Heart Fail 2007;9:942–8.
[31] Ho JE, Mahajan A, Chen MH, et al. Clinical and genetic correlates of growth differen-
tiation factor 15 in the community. Clin Chem 2012;58:1582–91.
